Profiling Antibody Drug Conjugate Positional Isomers: A System-of-Equations Approach
- 22 August 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (17), 7479-7486
- https://doi.org/10.1021/ac301568f
Abstract
Antibody drug conjugates enable the targeted delivery of potent chemotherapeutic agents directly to cancerous cells. They are made by the chemical conjugation of cytotoxins to monoclonal antibodies, which can be achieved by first reducing interchain disulfide bonds followed by conjugation of the resulting free thiols with drugs. This process yields a controlled, but heterogeneous, population of conjugated products that contains species with various numbers of drugs linked to different former interchain disulfide cysteine residues on the antibodies. We have developed a mathematical approach using inputs from capillary electrophoresis and hydrophobic interaction chromatography to determine the positional isomer distribution within a population of antibody drug conjugates. The results are confirmed by analyzing isolated samples of specific drug-to-antibody ratio species. The procedure is amenable to rapid determination of positional isomer distributions and features low material requirements. A survey of several antibody drug conjugates based on the same IgG framework and small molecule drug combination has shown a very similar distribution of isomers among all of the molecules using this technique, suggesting a robust conjugation process.Keywords
This publication has 26 references indexed in Scilit:
- Fully human antibodies from transgenic mouse and phage display platformsCurrent Opinion in Immunology, 2008
- Potent antibody therapeutics by designNature Reviews Immunology, 2006
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- Immunogenicity of engineered antibodiesMethods, 2005
- BR96 conjugates of highly potent anthracyclinesBioorganic & Medicinal Chemistry Letters, 2003
- Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Reshaping Human Antibodies: Grafting an Antilysozyme ActivityScience, 1988
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.Proceedings of the National Academy of Sciences, 1984
- Selective Destruction of Target Cells by Diphtheria Toxin Conjugated to Antibody Directed against Antigens on the CellsScience, 1970